Diabetes update: Ryzodeg® 70/30 Penfill® insulin
A new formulation of insulin will be available from 1 May 2025. Ryzodeg® 70/30 contains insulin degludec (an ultra-long-acting insulin) and insulin aspart (rapid acting mealtime insulin) administered in one injection. This is licensed for patients aged 6 years and over. This is the first true long-acting insulin funded in Aotearoa. It has an elimination half-life of 25 hours, so remains in the body for a few days. Ryzodeg® 70/30 insulin must therefore only be injected up to a maximum of twice daily, with particular care taken when prescribing for the elderly population.
Read more